As an important interface with the healthcare system for many patients, pharmacists are in a unique position to assist patients with quitting smoking, thereby improving patients’ pulmonary health. Because nicotine replacement therapy products and bupropion are available to patients largely via pharmacies, the pharmacist has become a logical candidate for providing smoking cessation assistance. Furthermore, research has shown that when pharmacists counsel patients on medications for quitting smoking, their intervention positively impacts smoking cessation rates. This article provides a review of methods for cessation and provides pharmacists with feasible and effective smoking cessation counseling strategies for implementation into everyday practice. The intervention approach draws heavily upon the U.S. Public Health Service Clinical Practice Guideline for Treating Tobacco Use and Dependence.
CDC. Achievements in public health, 1900- 1999: Tobacco use—United States, 1900-1999. MMWR. 1999; 48(43):986-993.
2.
CDC. Cigarette smoking-attributable mortality and years of potential life lost—United States, 1990. MMWR. 1993; 42(33):645-649.
3.
McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA.1993 Nov 10; 270(18):2207-2220.
4.
CDC. Smoking-attributable mortality and years of potential life lost—United States, 1984 (Editorial note—1997). MMWR.1997; 444-451.
5.
American Cancer Society. Cancer Facts and Figures, 2000: Atlanta, GA.
6.
Shopland DR. Tobacco use and its contributions to early cancer mortality with a special emphasis on cigarette smoking. Environ Health Perspect. 1995; 103 (suppl 8):131-142.
7.
Boffetta P, Pershagen G, Jöckel K-H, et al. Cigar and pipe smoking and lung cancer risk: a multi-center study from Europe. J Natl Cancer Inst. 1999; 91:697-701.
8.
Higgins IT, Mahan CM, Wynder EL. Lung cancer among cigar and pipe smokers. Prev Med. 1988; 17(1):116-128.
9.
Lubin JH, Richter BS, Blot WJ. Lung cancer risk with cigar and pipe use. J Natl Cancer Inst. 1984; 73(2):377-381.
10.
Lange P, Nyboe J, Appleyard M, et al. Relationship of the type of tobacco and inhalation pattern to pulmonary and total mortality. Eur Respir J. 1992 Oct; 5(9):1111-1117.
11.
Mitchell BE, Sobel HL, Alexander MH. The adverse health effects of tobacco and tobacco-related products. Prim Care. 1999; 26:463-498.
12.
Fielding JF, Husten CG, Eriksen MP. Tobacco: Health effects and control. In: Wallace RB, Doebbeling BN, Last JM, eds. Public Health and Preventive Medicine. 14th ed.Stamford, Connecticut: Appleton & Lange, 1998.
13.
Langhammer A, Johnsen R, Holmen J, et al. Cigarette smoking gives more respiratory symptoms among women than among men. The Nord-Trondelag Health Study (HUNT). J Epidemiol Comm Hlth. 2000; 54:917-922.
U.S. Public Health Service. Smoking and Health. Report of the Advisory Committee to the Surgeon General of the Public Service. U.S. Department of Health, Education, and Welfare. Public Health Service. Center for Disease Control. PHS Publication No. 1103, 1964.
16.
U.S. Public Health Service. Reducing the Health Consequences of Smoking: 25 Years of Progress. A Report of the Surgeon General. U.S. Department of Health and Human Services. Public Health Service. Centers for Disease Control. DHHS Publication No. (CDC) 89-8411, 1989.
17.
Woolcock AJ, Peat JK, Leeder SR, et al. The development of lung function in Sydney children: Effects of respiratory illness and smoking. Eur J Resp Dis. 1984; 65(suppl.):1-37.
18.
Dockery DW, Speizer FE, Ferris BG, et al. Cumulative and reversible effects of lifetime smoking on simple tests of lung function in adults. Am Rev Resp Dis. 1988; 137:286-292.
19.
Doll R, Crofton J.Tobacco and health. Br Med Bull. 1996; 52.
20.
Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA. 1994; 272:1497-1505.
21.
Wiebel FJ. Health effects of passive smoking. In: Bolliger CT, Fagerström KO, eds. The Tobacco Epidemic. Karger, Basel, Switzerland, pp. 107-121, 1997.
22.
Gold DR. Environmental tobacco smoke, indoor allergens, and childhood asthma. Environ Health Perspect. 2000; 108(suppl 4):643-651.
23.
Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000; 321:323-329.
24.
Fletcher C, Peto R.The natural history of chronic airflow obstruction. Br Med J. 1977 Jun 25; 1(6077):1645-1648.
25.
CDC. Cigarette smoking among adults—United States, 1998. MMWR. 2000; 49(39):881-884.
26.
CDC. Health objectives for the nation: Cigarette smoking among adults—United States, 1993. MMWR. 1994; 43(50):925-930.
27.
CDC. Smoking cessation during previous year among adults—United States, 1990 and 1991. MMWR. 1993; 42(46):504-507.
28.
Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: USDHHS. PHS. June 2000.
29.
West R, McNeill A, Raw M.Smoking cessation guidelines for health professionals: an update. Thorax. 2000; 55(12):987-999.
30.
Sinclair HZ, Bond CM, Lennox AS, et al. Training pharmacists and pharmacy assistants in the stage-of-change model of smoking cessation: A randomised controlled trial in Scotland. Tob Control. 1998; 7:253-261.
31.
Smith MD, McGhan WF, Lauger G.Pharmacist counseling and outcomes of smoking cessation. Am Pharm. 1995; NS35(8):20-29.
32.
McGhan WF, Smith MD. Pharmacoeconomic analysis of smoking-cessation interventions. Am J Health-Syst Pharm. 1996; 53:45-52.
33.
Hudmon KS, Prokhorov AV, Corelli RL, et al. Helping tobacco users to quit: Pharmacists’ counseling role. Presented at: American Society for Preventive Oncology 24th Annual Meeting, March 5-7, 2000, Bethesda, MD.
34.
McElnay JC, Maquire RA, Drummond A, et al. Smoking cessation: the contribution of community pharmacy. Dis Manage Health Outcomes. 2000; 8(3):147-158.
35.
Glynn TJ, Manley MW. How to Help Your Patients Stop Smoking: A National Cancer Institute Manual for Physicians. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute. NIH Publication No. 90-3064, 1990.
36.
Prochaska JO. Systems of Psychotherapy: A Transtheoretical Analysis. Homewood, IL: Dorsey Press; 1979.
37.
Prochaska JO, DiClemente CC, Norcross JC. Changing: process approaches to initiation and maintenance of changes. In: Klar Y, Fisher JD, Chinsky JMet al., eds. Self Change: Social Psychological and Clinical Perspectives. New York: Springer-Verlag; 1992:87-114.
38.
Prochaska JO, DiClemente CC. The Transtheoretical Approach: Crossing Traditional Boundaries of Therapy. Homewood, IL: Dow Jones-Irwin; 1984.
39.
Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: Applications to addictive behaviors. Am Psychol. 1992; 47(9):1102-1114.
40.
Ferry LH. Non-nicotine pharmacotherapy for smoking cessation. Prim Care. 1999; 26(3):653-669.
41.
Covey LS, Sullivan MA, Johnston JA, et al. Advances in non-nicotine pharmacotherapy for smoking cessation. Drugs. 2000; 59(1):17-31.
42.
Molander L, Lunell E, Fagerström KO. Reduction of tobacco withdrawal symptoms with a sublingual nicotine tablet: a placebo controlled study. Nicotine Tob Res. 2000 May; 2(2):187-191.
43.
Wallström M, Nilsson F, Hirsch JM. A randomized, double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation. Addiction. 2000; 1161-1171.
44.
Medical Economics Company, Inc.2000 Drug Topics Redbook. Montvale, NJ: November 2000.
45.
Fiore MC, Bailey WC, Cohen SJ, et al. A clinical practice guideline for treating tobacco use and dependence: A U.S. Public Health Service Report. JAMA. 2000; 283:32244-32254.
46.
Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999; 340:685-691.
47.
Prochaska JO, DiClemente CC. Stages of change in the modification of problem behaviors, in Hersen M, Eisler RM, Miller PM, eds. Progress in Behavior Modification. Newbury Park: Sage, 1992; 183-218.
48.
Hudmon KS, Berger BA. Pharmacy applications of the transtheoretical model in smoking cessation. Am J Health Syst Pharm. 1995; 2:282-287.
49.
Berger BA, Hudmon KS. Readiness for change: Implications for patient care. J Am Pharm Assn. 1997; 37:321-329.
50.
National Association of Chain Drug Stores. Chain community pharmacy: A vital link in the U.S. health care system. [On-line], 2000. Available: http://www.nacds.org/industry/industry_fr.html
